These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21386934)

  • 41. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
    Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
    J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
    Powers B; Greene L; Balfe LM
    J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers.
    Sierra C; de la Sierra A
    Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):435-41. PubMed ID: 16046901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
    Satoh M; Haga T; Hosaka M; Obara T; Metoki H; Murakami T; Kikuya M; Inoue R; Asayama K; Mano N; Ohkubo T; Imai Y
    J Hypertens; 2016 Jun; 34(6):1218-23. PubMed ID: 27027425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.
    Greathouse MK; Weir MR
    Postgrad Med; 2012 Mar; 124(2):40-52. PubMed ID: 22437214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.
    Timmermans PB
    Hypertens Res; 1999 Jul; 22(2):147-53. PubMed ID: 10487332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study.
    Lee W; Kang J; Park JB; Seo WW; Lee SY; Lim WH; Jeon KH; Hwang IC; Kim HL
    Health Sci Rep; 2023 Feb; 6(2):e1056. PubMed ID: 36741853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
    Neutel JM
    Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.